Mylan and Lupin have received market authorization for their etanercept biosimilar (Nepexto, YLB113) in Europe for all indications of the reference product.
Mylan and Lupin announced that the European Commission has approved their etanercept biosimilar (Nepexto, YLB113), which references Amgen and Pfizer’s Enbrel for the treatment of immune-mediated inflammatory diseases, such as rheumatoid arthritis. The biosimilar received marketing authorization for all indications of the reference product.
“This milestone reflects a strong scientific program behind [YLB113] and commitment by our teams and our partner, Lupin, to bring the product to market as soon as possible. We look forward to launching Nepexto in the second half of this year,” said Mylan President Rajiv Malik, in a statement.
Etanercept is a tumor necrosis factor (TNF) inhibitor also used for the treatment of juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, nonradiographic axial spondyloarthritis, plaque psoriasis, and pediatric plaque psoriasis.
Lupin CEO Vinita Gupta expressed that this is the first biosimilar to receive regulatory approval in Europe for the India-based company. “Biosimilars like [YLB113] will play a critical role in expanding access to patients in Europe, providing an effective treatment for multiple therapies, including rheumatoid arthritis,” she said in the statement.
Lupin and Mylan have been in collaboration since 2018 to commercialize a biosimilar etanercept in several global markets.
YLB113 is the third etanercept biosimilar to receive approval in Europe and the fifth biosimilar approved for Mylan for the European market.
Lupin also received marketing approval for YLB113 in Japan in collaboration with YL Biologics in March 2019.
Clinical Equivalency
The regulatory approval comes after the Committee for Medicinal Products for Human Use recommended YLB113 for use after reviewing a biosimilarity assessment that included preclinical and clinical study results that demonstrated bioequivalence to the reference product.
Additionally, YLB113 demonstrated equivalence to reference etanercept in terms of efficacy, safety, and immunogenicity in a phase 3 clinical trial for patients with moderate to severe active rheumatoid arthritis.
In 2019, reference etanercept, marketed by Amgen and Wyeth Pharmaceuticals, grossed $9.6 billion in global sales, according to IQVIA. The drug generated $5 billion for sales in the United States alone.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.